A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...
New drugs and therapies have become indispensable for treating an array of cancers. Unfortunately, they can also cause damage to the heart, a side effect that has led to the development of a new ...
A new study out of Harvard Medical School is opening the door for cancer patients with a rare but dangerous heart condition ...
There’s no “silver bullet” for this problem, which is largely driven by clinical inertia, but some efforts are chipping away ...
Via Christi is the first hospital in the region to perform a new procedure for atrial fibrillation for patients who can’t ...
Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...
FineHeart, a clinical-stage MedTech company developing innovative medical devices for heart failure, has achieved a major milestone in its ...
In this week’s View, Dr. Eagle looks at the consequences of discontinuing long-term drug treatment in patients with heart ...
After more heart failure hospitalization in the past 6 months. Presence of all the above despite 'attempts to optimize' therapy, including diuretics, renin-angiotensin-aldosterone system and ß ...
Failure is held up as a motivator ... In one study, participants predicted the likelihood that a heart attack survivor would make positive changes in their behavior. Without any additional ...
Background: Standard pharmacotherapy for patients with heart failure with reduced ejection fraction (HFrEF) comprises “quadruple therapy” with a renin–angiotensin system inhibitor, a β-blocker, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback